

\*\*\*\*New release May 2009\*\*\*\*

## DiseaseINFOPACK: Chikungunya virus (CAT: VADIP013)

<b>Proposal No/#PO</b>	:	<b>[Enter client specific #PO]</b>
<b>Product Name</b>	:	Comprehensive review/analysis of Chikungunya virus disease trends/dynamics
<b>Project Initiation Date</b>	:	n/a
<b>Billable days</b>	:	n/a
<b>Initiator(s)</b>	:	[Enter client name, function and address]
<b>Therapeutic Area</b>	:	<i>Emerging viruses</i>
<b>Product (if applicable)</b>	:	<b>CAT No:</b> VADIP013, published May 2009

## Background

Chikungunya virus (CHIK) is an arthropod-borne RNA virus (arbovirus) which causes an acute illness including fever, skin rash, and incapacitating arthralgia<sup>1</sup>. In some cases the virus can cause recurrent disease, neurological complications and severe neonatal disease (encephalopathy). Although CHIK is endemic in Africa/Southeast Asia, recent outbreaks during 2004–2007 have reached new geographical areas where cases are now reported in Europe, Hong-Kong, Canada, Taiwan and the USA. In some cases, these are directly associated with the return of infected tourists from India and islands of the Indian Ocean. Moreover, in 2007, the first CHIK outbreak was recorded in a temperate region of North Eastern of Italy with more than 200 cases<sup>2</sup>.

This expert report provides an up-to-date comprehensive review of current literature pertaining to Chikungunya virus including its epidemiology (outbreaks), surveillance and dynamics. The report seeks to explore whether the virus is a real emerging threat due to drivers such as global warming, changing distribution of Chikungunya virus vectors and population immunity. Lastly, past and current candidate vaccine-based approaches to Chikungunya virus are discussed.

---

<sup>1</sup> Robinson MC. An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952–53. I. Clinical features. *Trans R Soc Trop Med Hyg.* 1955;49(1):28–32

<sup>2</sup> Watson R. Europe witnesses first local transmission of chikungunya fever in Italy. *BMJ* 2007;335(7619):532-3

**PRODUCT CONTENTS:**

**Published May 2009 (CAT No: VADIP013)**

Executive summary  
The pathogen  
The vector  
Clinical features  
Clinical features (cont..)  
Host response  
Diagnosis  
Reporting and surveillance  
Treatment  
Prevention and control  
Epidemiology: overview  
Epidemiology: CHIK outbreaks/seroprevalence studies  
Epidemiology: Indian Ocean  
Epidemiology: India  
Epidemiology: India (cont..)  
Epidemiology: Italy  
Epidemiology: imported cases  
Epidemiology: imported cases (France)  
Epidemiology: summary of recent outbreaks (Map)  
Epidemiology: recent outbreaks  
Epidemiology: summary of recent outbreaks (Table)  
Mortality  
Mortality (cont..)  
Morbidity  
Morbidity (cont..)  
CHIK outbreaks associated with *Aedes albopictus*  
The global spread of *Aedes albopictus*  
Global distribution of *Aedes albopictus*  
Global distribution of *Aedes aegypti*  
European risk map for *Aedes albopictus*  
European risk map for *Aedes albopictus*  
Factors influencing risk of future CHIK epidemics  
CHIK Vaccine research: US military vaccine  
CHIK Vaccine research: new approaches  
CHIK Vaccine pipeline  
CHIK Vaccine pipeline (cont..)  
Appendix I – Bibliography  
Appendix II – About VacZine Analytics  
Disclaimer

**PAGES: ~40 MS Powerpoint slides, fully referenced/sourced. Available in .pdf form**

## PROJECT METHODOLOGY:

**VacZine Analytics** has conducted a comprehensive secondary research to review all available information regarding Chikungunya in major EU/Canada and US markets. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc.

## PRODUCT PRICE:

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- USD \$4895.00/ GBP £3265.00 (Region license)\*

\*A region is North America, Europe or ROW

For orders in the UK, VAT at 15% will be added to final invoice total

## HOW TO ORDER:

To order please contact your region account manager or order direct at [orders@vaczine-analytics.com](mailto:orders@vaczine-analytics.com)  
This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and the “spiral logo” are UK Registered Trademarks, 2009

## BIBLIOGRAPHY:

1. Schuffenaker I et al. Genome microevolution of Chikungunya viruses causing the Indian Ocean outbreak. PLOS Med 2006;3:1058-70
2. Paquet C, et al. Chikungunya outbreak in Réunion: epidemiology and surveillance, 2005 to early January 2006. Euro Surveill. 2006;11(5):pii=2891
3. Kaur P et al. Chikungunya outbreak, South India, 2006. Emerg Infect Dis. 2008 Oct;14(10):1623-5
4. Taubitz W et al. Chikungunya fever in travelers: clinical presentation and course. Clin Infect Dis. 2007 Jul 1;45(1):e1-4.
5. Simon F et al. Chikungunya infection: an emerging rheumatism among travelers returned from Indian Ocean islands. Report of 47 cases. Medicine (Baltimore). 2007 May;86(3):123-37.
6. Lemant J et al. Serious acute chikungunya virus infection requiring intensive care during the Réunion Island outbreak in 2005-2006. Crit Care Med. 2008 Sep;36(9):2536-41.
7. Rampal, Sharda M, et al. Neurological complications in Chikungunya fever. J Assoc Physicians India. 2007 Nov;55:765-9.
8. Tournebize P et al. [Neurological manifestations in Chikungunya: about 23 cases collected in Réunion Island]. Rev Neurol (Paris). 2009 Jan;165(1):48-51.
9. Lewthwaite P et al. Chikungunya virus and central nervous system infections in children, India. Emerg Infect Dis. 2009 Feb;15(2):329-31
10. Simon F et al. Chikungunya virus-induced myopericarditis: toward an increase of dilated cardiomyopathy in countries with epidemics? Am J Trop Med Hyg. 2008 Feb;78(2):212-3.
11. Robin S et al. Severe bullous skin lesions associated with Chikungunya virus infection in small infants. Eur J Pediatr. 2009 Apr 29.

12. Ledrans M et al. Outbreak of chikungunya in the French Territories, 2006: lessons learned. *Euro Surveill.* 2007;12(36):pii=3262
13. X. Fritel et al. Is Pregnancy Outcome Influenced by Chikungunya Infection? A Case-Control Study in 1401 Pregnant Women Enrolled in the CHIMERE Cohort. 13th ICID. June 19-22, 2008, Kuala Lumpur, Malaysia.
14. CDC. Chikungunya Fact Sheet. Available at: <http://www.cdc.gov>. Accessed: May 2009.
15. European Centre for Disease Prevention and Control. Chikungunya Fact sheet. Available at: <http://www.ecdc.europa.eu/>. Accessed: May 2009.
16. Panning M et al. No evidence of chikungunya virus and antibodies shortly before the outbreak on Sri Lanka. *Med Microbiol Immunol.* 2009 May;198(2):103-6.
17. Couderc T et al. A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. *PLoS Pathog.* 2008 Feb 8;4(2):e29
18. Litzba N et al. Evaluation of the first commercial chikungunya virus indirect immunofluorescence test. *J Virol Methods.* 2008 Apr;149(1):175-9.
19. De Lamballerie, X et al. On Chikungunya Acute Infection and Chloroquine Treatment. *Vector-Borne and Zoonotic Diseases.* December 2008, 8(6): 837-840
20. Dash PK et al. RNA interference mediated inhibition of Chikungunya virus replication in mammalian cells. *Biochem Biophys Res Commun.* 2008 Nov 28;376(4):718-22.
21. Edelman R et al Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. *Am J Trop Med Hyg.* 2000 Jun;62(6):681-5.
22. WHO. Weekly epidemiological record. No. 47, 2007, 82, 409–416. Available at: <http://www.who.int/>. Accessed: May 2009.
23. Laras K. Tracking the re-emergence of epidemic chikungunya virus in Indonesia. *Trans R Soc Trop Med Hyg.* 2005 Feb;99(2):128-41
24. Ravi V. Re-emergence of Chikungunya virus in India. *Indian J Med Microbiol* 2006; 24: 83-4.
25. Kariuki Njenga M et al. Tracking epidemic Chikungunya virus into the Indian Ocean from East Africa. *J Gen Virol.* 2008 Nov;89(Pt 11):2754-60.
26. Institut de Vielle Sanitaire. Chikungunya dans le monde. Point de situation au 29 avril 2008. Available at :<http://www.invs.sante.fr>. Accessed: May 2009
27. Directorate Of National Vector Borne Disease Control Programme. Chikungunya Fever Situation in the Country during 2006. Available at: <http://www.nvbdc.gov.in/>. Accessed: May 2009
28. Directorate Of National Vector Borne Disease Control Programme. Status Report On Dengue And Chikungunya As On 30.04.09. Available at: <http://www.nvbdc.gov.in/>. Accessed: May 2009
29. Seyler T, et al. Autochthonous chikungunya virus transmission may have occurred in Bologna, Italy, during the summer 2007 outbreak. *Euro Surveill.* 2008;13(3):pii=801
30. Depoortere E, Coulombier D, ECDC Chikungunya risk assessment group. Chikungunya risk assessment for Europe: recommendations for action. *Euro Surveill.* 2006;11(19):pii=2956.
31. Centers for Disease Control and Prevention (CDC). Update: chikungunya fever diagnosed among international travelers--United States, 2006. *MMWR Morb Mortal Wkly Rep.* 2007 Mar 30;56(12):276-7.
32. Mizuno Y et al. [First case of chikungunya fever in Japan with persistent arthralgia] *Kansenshogaku Zasshi.* 2007 Sep;81(5):600-1.
33. Krastinova E et al. Imported cases of chikungunya in metropolitan France: update to June 2006. *Euro Surveill.* 2006;11(34):pii=3030.
34. Pagès F et al. *Aedes albopictus* mosquito: the main vector of the 2007 Chikungunya outbreak in Gabon. *PLoS ONE.* 2009;4(3):e4691.
35. Tan, W. Chikungunya & Singapore: An Entomological Perspective. Available at: [www.redi.org.sg](http://www.redi.org.sg). Accessed: May 2009.
36. Bagi Minggu Epid Ke 47/2008 (16hb November Hingga 22hb November 2008). Available at: <http://www.moh.gov.my>. Accessed: May 2009.
37. Sergon K et al. Seroprevalence of Chikungunya virus infection on Grande Comore Island, union of the Comoros, 2005. *Am J Trop Med Hyg.* 2007 Jun;76(6):1189-93.
38. Beesoon S et al. Chikungunya fever, Mauritius, 2006. *Emerg Infect Dis.* 2008 Feb;14(2):337-8.
39. Outbreak news. Chikungunya and dengue, south-west Indian Ocean. *Wkly Epidemiol Rec.* 2006 Mar 24;81(12):106-8.
40. Yoosuf AA et al. First report of chikungunya from the Maldives. *Trans R Soc Trop Med Hyg.* 2009 Feb;103(2):192-6.
41. Josseran L et al. Chikungunya disease outbreak, Réunion Island. *Emerg Infect Dis.* 2006 Dec;12(12):1994-5.
42. Casolari S, et al. A fatal case of encephalitis associated with Chikungunya virus infection. *Scand J Infect Dis.* 2008;40(11-12):995-6.
43. Mavalankar D et al. Increased mortality rate associated with chikungunya epidemic, Ahmedabad, India. *Emerg Infect Dis.* 2008;14:412–5.
44. Renault P et al. Chikungunya-related fatality rates, Mauritius, India, and Réunion Island. *Emerg Infect Dis.* 2008 Aug;14(8):1327
45. Chikungunya deaths in the country: Report. 12 Oct 2006. Available at: <http://timesofindia.indiatimes.com/>. Accessed: May 2009.
46. Krishnamoorthy K et al. Burden of chikungunya in India: estimates of disability adjusted life years (DALY) lost in 2006 epidemic. *J Vector Borne Dis* 46, March 2009, pp. 26–35

47. Kumar NP et al. A226V mutation in virus during the 2007 chikungunya outbreak in Kerala, India. *J Gen Virol.* 2008 Aug;89(Pt 8):1945-8.
48. Arankalle VA et al. Genetic divergence of Chikungunya viruses in India (1963-2006) with special reference to the 2005-2006 explosive epidemic. *J Gen Virol.* 2007 Jul;88(Pt 7):1967-76.
49. Charrel RN, de Lamballerie X, Raoult D: Chikungunya outbreaks-the globalization of vector borne diseases. *N Engl J Med* 2007, 356:769-771
50. Reiskind MH et al. Susceptibility of Florida mosquitoes to infection with chikungunya virus. *Am J Trop Med Hyg.* 2008 Mar;78(3):422-5.
51. Medlock JM. Microbial Risk Assessment: Presentation before ECDC group on *Aedes albopictus* , Paris, October 22 2007.
52. Harrison VR et al. Production and evaluation of a formalin-killed Chikungunya vaccine. *J Immunol.* 1971 Sep;107(3):643-7.
53. McClain DJ, et al. Immunologic interference from sequential administration of live attenuated alphavirus vaccines. *J Infect Dis* 1988 177: 634–641.
54. Embassy of the United States of America . U.S. – France Cooperation On Chikungunya Vaccine . Available at: <http://france.usembassy.gov>. Accessed: May 2009.
55. Wang E et al. Chimeric alphavirus vaccine candidates for chikungunya. *Vaccine.* 2008 Sep 15;26(39):5030-9.
56. Muthumani K et al. Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. *Vaccine.* 2008 Sep 19;26(40):5128-34.
57. Tiwari M et al. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. *Vaccine.* 2009 Apr 21;27(18):2513-22.
58. Novel Vaccines – Need of the Developing World. Available at: <http://www.usp.org/>. Accessed: May 2009.

**TERMS and CONDITIONS:**

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on-line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. **Force Majeure:** The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, influenza pandemic, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request or at [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics**

Warren House  
Bells Hill  
Bishops Stortford  
Herts  
CM23 2NN  
United Kingdom  
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926  
E-mail: [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)

## About VacZine Analytics:

**VacZine Analytics** is a new strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and “the spiral logo” are UK Registered Trademarks, 2009



**VacZine Analytics**<sup>®</sup>

Bringing life to vaccine strategy...

Bringing life to vaccine strategy...

[www.vacZine-analytics.com](http://www.vacZine-analytics.com)

Warren House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44 (0) 1279 654514 **e-mail:** [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)

